-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-11-08
Values as of: 2024-11-08
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 19/06/2006
Primary Benchmark: S&P Pharms Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| CRTTF | Cortus Metals Inc | 4.57 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.88 (-0.59%) |
USD 40.46B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.29 (-0.41%) |
USD 2.91B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.65 (+0.58%) |
USD 1.19B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.78 (+0.84%) |
USD 0.22B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.15 (+0.57%) |
USD 0.15B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.37 (+0.87%) |
USD 0.13B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
+2.06 (+2.13%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.27 (+0.91%) |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.45 (-0.66%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.29 (+0.93%) |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 10.31 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -42.28% | 43% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -42.28% | 43% | F | 13% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -31.86% | 38% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.86% | 38% | F | 14% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -38.08% | 33% | F | 19% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -38.08% | 33% | F | 21% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.38% | 14% | F | 27% | F | ||
| Dividend Return | -0.70% | 14% | F | 19% | F | ||
| Total Return | 0.68% | 68% | D+ | 17% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.91% | 67% | D+ | 65% | D | ||
| Risk Adjusted Return | -4.39% | 10% | F | 20% | F | ||
| Market Capitalization | 0.50B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
